Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SarcoSIGHT: Fluorescence Guided Sarcoma Surgery vs Standard of Care
NCT07650656Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of indocyanine green in sarcoma (2 arms), sponsored by City of Hope. Primary endpoint: Unexpected positive margin rate at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT07650656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650656.